Jan 30,2017

Bigfoot Biomedical gets an undisclosed investment from JDRF

Milpitas, California-based Bigfoot Biomedical, a diabetes management company working on their first product, announced an investment from the Juvenile Diabetes Research Foundation (JDRF)’s newly launched venture fund, T1D, focused on early stage companies working on type 1 diabetes. The terms of the investment were not disclosed, but Bigfoot previously raised $35.5 million . The funding will be used to further develop Bigfoot’s automated insulin delivery service called smartloop. he cloud-connected diabetes management system is designed to interface with wearable insulin delivery and glucose monitoring tools, accessed through a companion app, and all delivered through a monthly bundled subscription service.

FUNDING
View Analyst & Ambassador Comments
Go to original news
Mar 16,2017

Livongo's $52.5M round will take it beyond diabetes and beyond the US

Technology-enabled diabetes management company Livongo Health has raised $52.5 million in new funding in a round co-led by General Catalyst, an existing investor, and international investment company Kinnevik. Other investors included Microsoft Ventures, American Investment Holdings, and EDBI, a Singapore-based fund whose portfolio includes WellTok, GoBalto, and Sotera Wireless. All previous investors also participated in the round.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Jun 28,2017

Diabetes management platform Glooko raises $35 million

Glooko, a startup selling data management healthcare service on top of a device-agnostic platform to make it easier for doctors to remotely monitor patients, has pulled in $35 million Series C funding. It had previously raised $36 million in various rounds, bringing the total up to $71 million.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jul 12,2017

With $18.3M in new funding, Solera Health looks beyond diabetes prevention

Solera Health, the Phoenix-based company that has created a marketplace for digital and in-person diabetes prevention programs, has raised $18.3 million in a round led by Adams Street Partners, with additional participation from Blue Cross Blue Shield Venture Partners, Sandbox Industries and SJF Ventures. The round, Solera's largest to date, brings its total funding to $30.3 million.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 27,2017

X.GLU smart glucose meter for kids wins Microsoft's Imagine Cup competition

Microsoft’s annual Imagine Cup, a global competition of high-tech student projects, reached its culmination this week accompanied by the usual pomp at the company’s headquarters in Redmond. The winner of the $100,000 grand prize and 365 days of bragging rights is X.GLU, a Czech team that created a custom smart glucose meter for children with diabetes.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Aug 02,2017

Fruit Street Health raises $3 million in doctors-only round

Fruit Street Health, a digital health and telemedicine company currently focused on delivering a digital diabetes prevention program, has raised $3 million in new funding from physician investors. Dr. Jeremy Tucker, a senior emergency medicine physician on the board of directors of Fruit Street, led the round, which brings the company's total funding to $8.4 million.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 07,2017

Brighter strengthens funding for autumn product launch

Based on the authorization of the Board, the Board has decided to issue a private placement of a total of SEK 6,400,000 and 1,600,000 shares, of which SEK 3,816,000 and 954,000 shares through settlement and 2,584,000 and 646,000 shares in cash, which strengthens the company's equity.

FUNDING POST IPO-EQUITY
View Analyst & Ambassador Comments
Go to original news
Aug 23,2017

DarioHealth Closes on $5 Million Through Private Placement Offerings

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has closed on concurrent private placement offerings with domestic and non-U.S. investors for the sale of shares of the Company's common stock and shares of the Company's newly designated Series B Convertible Preferred Stock in concurrent private placement offerings. As a part of these private placement transactions, which totals $5 million in the aggregate before expenses and placement agent fees, the Company issued 483,333 shares of common stock at a price per share of $1.80 and 2,307,654 shares of Series B Convertible Preferred Stock at a price per share of $1.80. Investors in the offering included existing investors, as well as new investors including SC Fundamental Value Fund, L.P. and Pegasus Capital II, L.P.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Oct 05,2017

With $32M loan, connected glucometer pioneer AgaMatrix will split company into CGM, BGM businesses

AgaMatrix , the medical device that launched the first ever iPhone-connected glucometer , has secured a $32 million loan in order to reorganize the company into two distinct entities: AgaMatrix, which will continue to focus on Bluetooth-enabled glucometer's such as the company's newest Jazz Wireless 2 device, and WaveForm Technologies, which will be focused on the development of a proprietary continuous glucose monitoring product based on technology acquired from iSense CGM and Bayer Healthcare in 2016. A new holding company called AgaMatrix Holdings will own 100 percent of the stock in both businesses.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Nov 27,2017

Minimally Invasive CGM company Biolinq raises $10 million in Series A funding

San Diego-based Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $10 million in Series A financing. The round was led by M Ventures, in collaboration with Hikma Ventures. Biolinq is currently working on a skin applied, minimally-invasive electrochemical biosensor platform for diabetes patients, which analyzes biomarkers in the interstitial fluid to provide actionable health information. The funding will enable the company to expand its team, and get its product through the clinical validation trials necessary for FDA approval.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING